Journal of Tissue Viability:微电流疗法(EMT)能够有效促进伤口愈合

2021-12-16 小文子 MedSci原创

EMT是一种有效、安全的治疗方法,可改善伤口面积、愈合时间和疼痛。

微电流疗法(EMT)在伤口愈合过程中产生的内源性电场在细胞迁移和上皮伤口愈合中起着重要作用。Journal of Tissue Viability杂志的一项研究探讨了EMT改善急慢性伤口患者伤口愈合和疼痛的有效性和安全性。

研究人员检索相关文献,纳入截至2020年8月1日发表的评估EMT在伤口愈合有效性的随机临床试验。主要结局为伤口表面积、愈合时间和愈合的伤口数量。次要结局是疼痛感和不良事件。

纳入8项RCT研究进行定性总结,7项RCT研究进行定量分析(n = 337)。3项试验应用的波形为方形脉冲,2项研究中使用直流电。脉冲电流的频率在0.5 ~ 10Hz之间,电流强度范围为15 ~ 500 μA。3项试验采用低强度电流(≤100 μA),2项试验采用高强度电流(300 μA和500 μA),1项研究应用高强度和低强度电流(40μ- 500μ)。评价伤口愈合的主要结局为:3项研究评价了伤口表面积,4项研究评价了伤口完全愈合时间,2项研究评价了伤口愈合的数量。

EMT联合标准伤口护理(SWC)使得伤口愈合加快(MD=-8.3 cm2; 95% CI: -10.5 ~ -6.0)和愈合时间缩短(MD =-7.0 d; 95% CI:-11.9 ~ -2.1)。但是,愈合伤口的数量没有差异(RR = 2.0; 95% CI: 0.5 ~ 9.1],证据质量较低。EMT降低了感知疼痛(MD =-1.4; 95% CI: -2.7 ~ -0.2),两组间不良反应无差异(风险差异 = 0.05; 95% CI: -0.06 ~ 0.17)。

结果表明,EMT是一种有效、安全的治疗方法,可改善伤口面积、愈合时间和疼痛。临床研究应设计更加详细的干预参数和方案验证临床结局,以降低偏倚风险。

原文出处:

Juan Avendaño-Coy, Electrical microcurrent stimulation therapy for wound healing: A meta-analysis of randomized clinical trials. Journal of Tissue Viability, https://doi.org/10.1016/j.jtv.2021.12.002.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911395, encodeId=eafa191139516, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Aug 18 18:16:56 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081770, encodeId=71471081e70e9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 12:26:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081582, encodeId=4dd11081582ae, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09985652468, createdName=ms6000000145764456, createdTime=Sat Dec 18 18:58:30 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309917, encodeId=8026130991edf, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462140, encodeId=d0131462140b0, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-08-18 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911395, encodeId=eafa191139516, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Aug 18 18:16:56 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081770, encodeId=71471081e70e9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 12:26:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081582, encodeId=4dd11081582ae, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09985652468, createdName=ms6000000145764456, createdTime=Sat Dec 18 18:58:30 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309917, encodeId=8026130991edf, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462140, encodeId=d0131462140b0, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-19 一己怀

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1911395, encodeId=eafa191139516, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Aug 18 18:16:56 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081770, encodeId=71471081e70e9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 12:26:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081582, encodeId=4dd11081582ae, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09985652468, createdName=ms6000000145764456, createdTime=Sat Dec 18 18:58:30 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309917, encodeId=8026130991edf, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462140, encodeId=d0131462140b0, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-18 ms6000000145764456

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1911395, encodeId=eafa191139516, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Aug 18 18:16:56 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081770, encodeId=71471081e70e9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 12:26:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081582, encodeId=4dd11081582ae, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09985652468, createdName=ms6000000145764456, createdTime=Sat Dec 18 18:58:30 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309917, encodeId=8026130991edf, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462140, encodeId=d0131462140b0, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1911395, encodeId=eafa191139516, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Aug 18 18:16:56 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081770, encodeId=71471081e70e9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Dec 19 12:26:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081582, encodeId=4dd11081582ae, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09985652468, createdName=ms6000000145764456, createdTime=Sat Dec 18 18:58:30 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309917, encodeId=8026130991edf, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462140, encodeId=d0131462140b0, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Sat Dec 18 14:16:56 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-18 lfcmxl

相关资讯

NAT COMMUN:线粒体控制伤口愈合和肿瘤生长过程中的血管生成

血管是一个高度可塑性的组织,在血管生成过程中能够从静止状态切换到活跃的增殖状态。在此过程中,内皮细胞(ECs)的代谢重编程是至关重要的,以满足生长条件下不断增加的细胞能量需求。

Cell Stem Cell:毛囊真皮干细胞仅起到次要作用,它才是伤口愈合的主要推手!

我们在进化中选择了快速的伤口愈合方式,因而,在深层皮肤损伤之后,我们无法再生功能性真皮及其中的附件。有趣的是,全层切除皮肤伤口一些组织再生的能力,已经在小鼠中得到证明。长期以来,人们一直认为毛囊(HF

J Periodontal Res:L-PRF和A-PRF对牙周成纤维细胞体外伤口愈合的影响

L-PRF和A-PRF+是用于牙周再生手术的自体材料,均来源于患者的血液,但特点不同,对牙周组织成纤维细胞的影响存在争议。

Immunity:陈万军团队揭示TGF-β促进树突状细胞分泌白介素-31是伤口愈合过程中产生瘙痒的主要原因

神经系统可通过细胞间接触以及可溶性因子的释放调节免疫反应。尽管已知能引起瘙痒的因素有很多,但伤口愈合过程中免疫反应介导的瘙痒的主要因素和潜在机制仍然并不清楚。

Aging Cell:老年人伤口愈合为何更困难?

在这项概念验证研究中,研究人员使用双活检实验设计,在24名健康受试者中调查了人类伤口愈合过程中p16、p21和其他衰老相关生物标志物的表达。

Immunity:伤口愈合瘙痒治疗有望,IL-31才是元凶!

细胞因子TGF-β能够诱导真皮树突状细胞表达IL-31,从而激活感觉神经元并产生瘙痒。